IFF eyeing acquisitions once more because it sells off pharma unit—however no extra ‘Frutaroms’

On a name with Wall Avenue analysts after the Fortune 500 firm reported its 2024 outcomes, CEO Erik Fyrwald made it clear that acquisitions have been again on the desk—however with a extra disciplined strategy. Learn Extra